1. Bartley GB. Rundle and His Curve. Arch Ophthalmol 2011; 129: 356.
2. Kalmann R, Mourits MP. Late recurrence of unilateral graves orbitopathy on the contralateral side. Am J Ophthalmol 2002; 133: 727–729.
3. Hiromatsu Y, Eguchi H, Tani J, et al. Graves' ophthalmopathy: epidemiology and natural history. Intern Med 2014; 53(5): 353-360.
4. Tvito-Green R, Reich E, Robenshtok E, et al. Third-Generation Elisa Thyrotropin-Receptor Antibody Levels as an Adjuvant Tool to Guide Management of Patients with Graves Orbitopathy. Endocr Pract 2014; 20: 145–149.
5. Dolman PJ. Evaluating Graves’ Orbitopathy. Best Pract Res Cl En 2012; 26: 229–248.
6. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21: 593–646.
7. Breiman L. Random forests. Mach Learn 2001; 45: 5–32.
8. Bartalena L. Prevention of Graves’ ophthalmopathy. Best Pract Res Cl En 2012; 26: 371–379.
9. Bhatti MT, Dutton JJ. Thyroid Eye Disease: Therapy in the Active Phase. J Neuro-Ophthalmol 2014; 34: 186–97.
10. Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 2016; 5: 9–26.
11. Wiersinga WM, Perros P, Kahaly GJ, et al. Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006; 155:387–389.
12. Biau G. Analysis of a random forests model. J Mach Learn Res 2012; 13: 1063–1095.
13. Malley JD, Malley KG, Pajevic S. Statistical Learning for Biomedical Data. Cambridge Univ Press 2011; 137–154.
14. Bylander T. Estimating Generalization Error on Two-Class Datasets Using Out-of-Bag Estimates. Mach Learn 2002; 48: 287-297.
15. Couronné R, Probst P, Boulesteix A-L. Random forest versus logistic regression: a large-scale benchmark experiment. BMC Bioinformatics 2018; 19: 270.
16. Bartalena L, Tanda ML. Clinical practice. Graves’ ophthalmopathy. N Engl J Med 2009; 360: 994–1001.
17. Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010; 362: 726–738.
18. Lytton SD, Ponto KA, Kanitz M, et al. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of graves’ orbitopathy. J Clin Endocrinol Metab 2010; 95: 2123–2131.
19. Gerding MN, van der Meer JWC, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy: TSH receptor antibodies and Graves’ ophthalmopathy.
Clin Endocrinol 2000; 52: 267–271.
20. Nicolì F, Lanzolla G, Mantuano M, et al. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy. J Endocrinol Invest 2021; 44: 581–585.
21. Turck N, Eperon S, De Los Angeles Gracia M, et al. Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future. Dis Markers 2018; 2018: 1–9.
22. Venditti P, Meo SD. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci 2006; 63: 414–434.
23. Choi W, Li Y, Ji YS, et al. Oxidative stress markers in tears of patients with Graves’ orbitopathy and their correlation with clinical activity score. BMC Ophthalmol 2018; 18: 303.
24. Londzin-Olesik M, Kos-Kudla B, Nowak A, et al. The effect of thyroid hormone status on selected antioxidant parameters in patients with Graves’ disease and active thyroid-associated orbitopathy. Endokrynol Pol 2020;71(5):418-424.
25. Askland KD, Garnaat S, Sibrava NJ, et al. Prediction of remission in obsessive compulsive disorder using a novel machine learning strategy. Int J Methods Psychiatr Res 2015; 24(2): 156.
26. Stekhoven DJ, Bühlmann P. MissForest – non-parametric missing value imputation for mixed-type data. Bioinformatics 2012; 28: 112–118.